Physician profile
Kimberly Lyn Marsh
NPI 1134634520
$2,593.55
in general payments reported to CMS, 2019-2025
20 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what 95% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $172 · 2023: $186 · 2024: $936 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,421.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $503.13 | 2023-2025 | |
| Lundbeck LLC | $353.80 | 2024-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $348.27 | 2022-2025 | Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $220.37 | 2024-2025 | |
| Lilly USA, LLC | $217.17 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Novartis Pharmaceuticals Corporation | $121.22 | 2024-2025 | |
| Argenx US, INC. | $104.79 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $96.82 | 2024-2025 | Xeomin |
| Pfizer INC. | $93.87 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $89.45 | 2022 | |
| Biogen, INC. | $78.53 | 2025 | Zurzuvae, Tysabri, Vumerity |
| Amneal Pharmaceuticals LLC | $71.23 | 2024-2025 | Crexont, Ongentys |
| Ucb, INC. | $70.37 | 2024-2025 | Zilbrysq, Briviact |
| Neurocrine Biosciences, INC. | $67.84 | 2025 | |
| Alexion Pharmaceuticals, INC. | $50.17 | 2024 | Ultomiris |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $26.65 | 2024 | Nourianz |
| Ipsen Biopharmaceuticals, INC | $25.90 | 2025 | Dysport |
| Acadia Pharmaceuticals INC | $22.62 | 2025 | Nuplazid |
| Mdd US Operations, LLC | $16.30 | 2023 | Gocovri |
| E.R. Squibb & Sons, L.L.C. | $15.05 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.